PriceTargets.com logo

Aurinia Pharmaceuticals - AUPH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $17.75
  • Forecasted Upside: 6.61%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$16.65 As of 10/30/2026 05:00 PM ET
▼ -0.56 (-3.25%)

This chart shows the closing price for AUPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aurinia Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUPH

Analyst Price Target is $17.75
▲ +6.61% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aurinia Pharmaceuticals in the last 3 months. The average price target is $17.75, with a high forecast of $21.00 and a low forecast of $16.00. The average price target represents a 6.61% upside from the last price of $16.65.

This chart shows the closing price for AUPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 7 polled investment analysts is to moderate buy stock in Aurinia Pharmaceuticals. This rating has held steady since August 2026, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2026
  • 1 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2026
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2026

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/22/2026Weiss RatingsUpgradeBuy (B-) ➝ Buy (B)
10/21/2026TD CowenBoost TargetBuy ➝ Buy$17.00 ➝ $18.00
8/26/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
8/20/2026Bloom BurtonUpgradeHold ➝ Strong-Buy
8/12/2026Weiss RatingsReiterated RatingHold (C+) ➝ Hold (C+)
8/7/2026Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$15.00 ➝ $16.00
7/21/2026Zacks ResearchDowngradeStrong-Buy ➝ Hold
6/29/2026Zacks ResearchUpgradeHold ➝ Strong-Buy
5/15/2026Weiss RatingsDowngradeBuy (B-) ➝ Hold (C+)
5/1/2026Weiss RatingsUpgradeHold (C+) ➝ Buy (B-)
1/21/2026Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/3/2025Leerink PartnersDowngradeOutperform ➝ Market Perform$15.00 ➝ $16.00
12/3/2025Leerink PartnersDowngradeStrong-Buy ➝ Hold
11/7/2025Jefferies Financial GroupUpgradeHold ➝ Buy$10.00 ➝ $21.00
11/5/2025Bloom BurtonDowngradeModerate Buy ➝ Hold
11/5/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Sector Perform$9.00 ➝ $15.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
8/1/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$8.00 ➝ $9.00
7/30/2025HC WainwrightReiterated RatingBuy$17.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$10.00 ➝ $10.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$10.00 ➝ $10.00
9/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$13.00
2/23/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$12.00 ➝ $10.00
2/22/2024HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $13.00
2/16/2024Jefferies Financial GroupLower TargetHold$9.50 ➝ $9.00
2/16/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$13.00 ➝ $8.00
9/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
8/7/2023HC WainwrightBoost TargetBuy ➝ Buy$14.00 ➝ $15.00
5/2/2023Royal Bank Of CanadaBoost TargetOutperform$11.00 ➝ $13.00
2/23/2023Royal Bank Of CanadaReiterated RatingOutperform$11.00
1/3/2023Royal Bank Of CanadaBoost TargetOutperform$10.00 ➝ $11.00
11/7/2022HC WainwrightLower TargetBuy$26.00 ➝ $14.00
11/4/2022Royal Bank Of CanadaLower TargetOutperform$18.00 ➝ $10.00
11/4/2022Leerink PartnersLower TargetOutperform$17.00 ➝ $12.00
11/4/2022OppenheimerDowngradeOutperform ➝ Market Perform
8/9/2022HC WainwrightLower TargetBuy$30.00 ➝ $26.00
8/8/2022OppenheimerLower TargetOutperform$15.00 ➝ $13.00
8/5/2022Royal Bank Of CanadaLower TargetOutperform$22.00 ➝ $18.00
5/4/2022HC WainwrightLower Target$33.00 ➝ $30.00
4/28/2022Cantor FitzgeraldReiterated RatingOverweight
4/28/2022Royal Bank Of CanadaLower TargetOutperform$27.00 ➝ $22.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/8/2022Leerink PartnersLower TargetOutperform$30.00 ➝ $22.00
3/1/2022HC WainwrightReiterated RatingBuy$40.00 ➝ $33.00
3/1/2022Royal Bank Of CanadaLower TargetOutperform$31.00 ➝ $27.00
2/23/2022Royal Bank Of CanadaLower TargetOutperform$34.00 ➝ $31.00
12/15/2021Jefferies Financial GroupReiterated RatingBuy
12/10/2021OppenheimerUpgradeMarket Perform ➝ Outperform$33.00 ➝ $31.00
11/4/2021OppenheimerBoost TargetMarket Perform$32.00 ➝ $33.00
11/4/2021HC WainwrightBoost TargetBuy$35.00 ➝ $40.00
11/4/2021Leerink PartnersBoost TargetOutperform$28.00 ➝ $35.00
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2026
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2026

Current Sentiment

  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aurinia Pharmaceuticals logo
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Read More

Today's Range

Now: $16.65
Low: $16.48
High: $17.04

50 Day Range

MA: $16.49
Low: $15.69
High: $17.36

52 Week Range

Now: $16.65
Low: $12.07
High: $19.25

Volume

960,811 shs

Average Volume

774,388 shs

Market Capitalization

$2.22 billion

P/E Ratio

7.27

Dividend Yield

N/A

Beta

1.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Aurinia Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Aurinia Pharmaceuticals in the last twelve months: Bloom Burton, Jefferies Financial Group Inc., Leerink Partners, Royal Bank Of Canada, TD Cowen, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for AUPH.

What is the current price target for Aurinia Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Aurinia Pharmaceuticals in the last year. Their average twelve-month price target is $17.75, suggesting a possible upside of 6.6%. Jefferies Financial Group Inc. has the highest price target set, predicting AUPH will reach $21.00 in the next twelve months. Royal Bank Of Canada has the lowest price target set, forecasting a price of $16.00 for Aurinia Pharmaceuticals in the next year.
View the latest price targets for AUPH.

What is the current consensus analyst rating for Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals currently has 3 hold ratings, 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AUPH.

What other companies compete with Aurinia Pharmaceuticals?

Other companies that are similar to Aurinia Pharmaceuticals include Protagonist Therapeutics, ImmunityBio, TG Therapeutics, Arrowhead Pharmaceuticals and Abivax. Learn More about companies similar to Aurinia Pharmaceuticals.

How do I contact Aurinia Pharmaceuticals' investor relations team?

Aurinia Pharmaceuticals' physical mailing address is #140, 14315 – 118 Avenue, Edmonton, AB, T5L 4S6. The biotechnology company's listed phone number is 250-708-4272 and its investor relations email address is [email protected]. The official website for Aurinia Pharmaceuticals is www.auriniapharma.com. Learn More about contacing Aurinia Pharmaceuticals investor relations.